Publish the evidence.
A full, transparent assessment of the scientific record before any restriction is proposed or adopted.
The appeal
Patients’ Right to Access CBD and Transparent Decision-Making
An open appeal by an international coalition of patient organisations · published June 2026 · open for signatures and for additional organisations to join.
Read or download
The full appeal
The full appeal text is maintained and approved as its own document. This page hosts the approved PDF in five languages; the executive summary below lists what the coalition asks.
Available in EN / CZ / ES / FR / DE.
Executive summary — what the coalition asks
No covert restrictions.
No administrative measures without open public debate, a proportionality test, and a patient-impact assessment.
Regulate, don’t prohibit.
Proportionate rules: quality standards, contaminant testing, clear labelling, age restrictions where relevant.
Act on the real threat.
Enforcement against synthetic cannabinoids sold as “collector’s items” — not against tested products patients rely on.
A seat at the table.
Patient organisations formally consulted in every decision that affects access to treatment.
Timeline
- 24 February 2026
INCB issues internal PP Notice No. 1/2026 on cannabidiol.
- March–May 2026
Public statements in several states frame CBD as a “precursor of synthetic drugs”.
- 5 June 2026
The Czech government moves its CBD restriction proposal into the inter-ministerial comment procedure.
- 10 June 2026
The coalition publishes this appeal.
- [Date TBC] TBC
Comment-procedure deadline; the coalition files its formal submission.
The final entry stays a placeholder until the deadline is confirmed.